As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

In other recent news, SpringWorks Therapeutics has been in the spotlight with several key developments. The company is set to be acquired by Merck (NSE:PROR) KGaA, a move that TD Cowen analysts ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

In other recent news, SpringWorks Therapeutics has been in the spotlight with several key developments. The company is set to be acquired by Merck (NSE:PROR) KGaA, a move that TD Cowen analysts ...

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

FRANKFURT: German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 ...

FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for ...